Skip to main content

Advertisement

Log in

Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Purpose

HER2 gene is a member of the epidermal growth factor receptor (EGFR) family. Across different malignancies, aberrations of HER2 gene commonly correspond to gain-of-function alterations leading to increased receptor signaling.

Methods

We have reviewed the literature currently available on HER2 mutations in human breast cancer (BC) evaluating type and frequency of such mutations. The primary objective was to determine the frequency and the number of patients with HER2-mut in the series analyzed. The secondary objectives were to assess characteristics of mutated cases (ER and HER2 status and stage of disease, type of mutations, and finally the clinical outcome if reported).

Results

We retrieved 31 published papers, and the pooled rate of HER2 mutations across 12,905 BC patients was calculated. Overall, the frequency of HER2 mutations was 2.7% with most involving the intracellular domain. About 4% of patients were finally mutated. The predictive role was not described. Only 30% of these patients were simultaneously HER2 positive and 63% were ER positive.

Conclusion

We have found that the prevalence of HER2 mutations is about 3%. These genic alterations are independently associated with HER2 amplification status, occurring in both ER-positive/HER2-negative diseases or HER2-enriched cancers. Ongoing trials are investigating small molecules tyrosine kinase inhibitors in patients harboring these mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976

    Article  CAS  PubMed  Google Scholar 

  2. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ et al (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254–264

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of so. Am J Pathol 151:1523–1530

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M et al (1999) The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc Natl Acad Sci USA 96:4995–5000

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Giatromanolaki A (2004) c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1 dependent. Clin Cancer Res 10:7972–7977

    Article  CAS  PubMed  Google Scholar 

  6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

    Article  CAS  PubMed  Google Scholar 

  7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792

    Article  CAS  PubMed  Google Scholar 

  8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  CAS  PubMed  Google Scholar 

  9. Luque-Cabal M, García-Teijido P, Fernández-Pérez Y, Sánchez-Lorenzo L, Palacio-Vázquez I (2016) Mechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome it. Clin Med Insights Oncol 10:21–30

    PubMed  PubMed Central  Google Scholar 

  10. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25–38

    Article  PubMed  Google Scholar 

  11. Kancha RK, von Bubnoff N, Bartosch N, Peschel C, Engh RA, Duyster J (2011) Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS ONE 6:e26760

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM et al (2015) Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist 20:7–12

    Article  CAS  PubMed  Google Scholar 

  13. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224–237

    Article  CAS  PubMed  Google Scholar 

  14. Xu X, De Angelis C, Burke KA et al (2017) HER2 Reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2(+) breast cancer. Clin Cancer Res

  15. Greulich H, Kaplan B, Mertins P, Chen T-H, Tanaka KE, Yun C-H et al (2012) Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 109:14476–14481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Trowe T, Boukouvala S, Calkins K, Cutler RE, Fong R, Funke R et al (2008) EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res 14:2465–2475

    Article  CAS  PubMed  Google Scholar 

  17. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D et al (2015) HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci USA 112:E6205–E6214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ibrahim EM, Kazkaz GA, Al-Mansour MM, Al-Foheidi ME (2015) The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysis. Breast Cancer Res Treat 152:463–476

    Article  CAS  PubMed  Google Scholar 

  19. Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL et al (2016) HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol 11:414–419

    Article  PubMed  Google Scholar 

  20. Wen W, Chen W, Xiao N, Bender R, Ghazalpour A, Tan Z et al (2017) Mutations in the kinase domain of the HER2/ERBB2 gene identified in a wide variety of human cancers. J Mol Diagnostics 17:487–495

    Article  Google Scholar 

  21. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M et al (2013) Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 31:1997–2003

    Article  PubMed  Google Scholar 

  22. Perera SA, Li D, Shimamura T, Raso MG, Ji H, Chen L et al (2009) HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci USA 106:474–479

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS et al (2017) Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. J Clin Oncol 32:68–75. doi:10.1200/JCO.2012.47.2787

    Article  Google Scholar 

  24. Groenendijk FH, de Jong J, Fransen van de Putte EE, Michaut M, Schlicker A, Peters D et al (2016) ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69:384–388

    Article  CAS  PubMed  Google Scholar 

  25. Hyman DM, Piha-Paul SA, Rodon J et al. Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2” basket” study

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Fausto Petrelli.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Petrelli, F., Tomasello, G., Barni, S. et al. Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. Breast Cancer Res Treat 166, 339–349 (2017). https://doi.org/10.1007/s10549-017-4419-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-017-4419-x

Keywords

Navigation